Debut Plus

₹7.08

▼ -0.4 -5.35%

18 Jul 2026

BSE Listed

Vista Pharmaceuticals Ltd. (524711)

Volume: 5,885Avg Vol 1W: 3,309Avg Vol 1M: 7,00152W Range:₹5.71₹11.69
BSE www.vistapharmaceuticals.com
Key Ratios
Checked 4h ago
Market Cap₹44 Cr
Current Price₹7.08
Previous Close₹7.48
High / Low (52w)₹11.69 / ₹5.71
Volume5,885
Avg Vol (1W)3,309
Avg Vol (1M)7,001
Stock P/E—
Book Value₹5.92
Dividend Yield0%
ROE-33.1%
ROA-21.9%
Revenue (TTM)—
Revenue Growth—
Profit Margin-223.33%
Total Debt—
Shares Outstanding6 Cr
Face Value—
EPS (TTM)₹0
P/B1.2
Debt / Equity0.18
50 DMA₹7.47
200 DMA₹8
Day change-5.35%
Price Chart
₹7.08▼ 37.46% · 1Y
₹11₹62.3L
2025-07-17
2026-07-17

20-day avg volume: 7K shares

Pros
  • Company is almost debt-free.
Cons
  • Company is loss-making at the latest annual result.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹2 Cr₹2 Cr₹3 Cr₹3 Cr₹2 Cr₹1 Cr₹2 Cr₹0 Cr
EBITDA₹-1 Cr₹-1 Cr₹-2 Cr₹-1 Cr₹-1 Cr₹-3 Cr₹-3 Cr₹-7 Cr
Net Profit₹-1 Cr₹-1 Cr₹-1 Cr₹-1 Cr₹-1 Cr₹-3 Cr₹-2 Cr₹-6 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹29 Cr₹34 Cr₹27 Cr₹1 Cr₹1 Cr₹1 Cr₹11 Cr₹11 Cr
EBITDA₹4 Cr₹3 Cr₹-2 Cr₹-2 Cr₹-2 Cr₹-5 Cr₹-4 Cr₹-4 Cr
Net Profit₹2 Cr₹1 Cr₹-4 Cr₹-2 Cr₹-1 Cr₹-6 Cr₹-5 Cr₹-5 Cr
EPS0.730.3-1.22-0.54-0.24-0.9-0.75-0.79
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹53 Cr₹53 Cr₹51 Cr₹51 Cr₹56 Cr₹56 Cr₹58 Cr₹60 Cr
Total Liabilities₹21 Cr₹17 Cr₹21 Cr₹18 Cr₹20 Cr₹19 Cr₹18 Cr₹15 Cr
Equity₹32 Cr₹36 Cr₹30 Cr₹33 Cr₹35 Cr₹37 Cr₹40 Cr₹45 Cr
Total Debt————————
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹-7 Cr₹-1 Cr₹-3 Cr₹-5 Cr₹-7 Cr
Investing₹0 Cr₹0 Cr₹-1 Cr₹-1 Cr₹0 Cr
Financing₹7 Cr₹1 Cr₹3 Cr₹6 Cr₹8 Cr
Free Cash Flow₹-7 Cr₹-1 Cr₹-3 Cr₹-5 Cr₹-7 Cr
Shareholding
Promoter 21.19% Institutions 0.02% Public 78.79%
Efficiency & Working Capital
ROCE-32.4%
Interest Coverage-4.4
Dividend Payout—
Debtor Days491 d
Inventory Days298 d
Payable Days203 d
Cash Conversion Cycle586 d
Working Capital Days789 d
Shareholding Details

As of 2026-03-31

Promoter21.2%
FII0%
DII0%
Institutions0%
Public78.8%
Promoter Pledge0%
No. of Shareholders14,154
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodJun 2023Sept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Promoters30.5%29.5%27.8%27.8%21.2%21.2%21.2%21.2%21.2%21.2%21.2%21.2%
FIIs0%0%0%0%0%0%0%0%0%0%0%0%
DIIs0%0%0%0%0%0%0%0%0%0%0%0%
Public69.5%70.5%72.2%72.2%78.8%78.8%78.8%78.8%78.8%78.8%78.8%78.8%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders14,64814,25013,90814,01513,88213,91314,08614,15814,06114,01214,08014,154
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Murali MeragaPublic Shareholding14.6%90,00,000
Pavan Sathvik GilakaPublic Shareholding12.6%77,58,000
Umakanth KattaPublic Shareholding12.3%75,38,465
Vista Pharmaceuticals IncShareholding of Promoter and Promoter Group10.7%65,79,620
Dhananjaya AlliShareholding of Promoter and Promoter Group4.7%28,87,424
Suresh GadalayPublic Shareholding4.6%28,53,704
Kamal GadalayPublic Shareholding3%18,64,133
Vasant V AlliShareholding of Promoter and Promoter Group2.6%16,01,478
Deepthi PachipalaPublic Shareholding2.4%15,00,000
Chittajallu Naga KeerthiPublic Shareholding2.4%15,00,000
Keshava Murthy Shiva ShankarPublic Shareholding2%12,55,158
Telangana State Industrial Development Corporation LimitedShareholding of Promoter and Promoter Group1.2%7,50,000
Rajendar BalakrishnaPublic Shareholding1.1%7,00,000
Ramaswamy Reddy PedinekaluvaPublic Shareholding1.1%6,85,302
Padmavathi AlliShareholding of Promoter and Promoter Group0.8%4,63,666
Vamsi V AlliShareholding of Promoter and Promoter Group0.7%4,16,666
Roshni AlliShareholding of Promoter and Promoter Group0.6%3,41,333
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Telangana State Industrial Development Corporation Limited00%2026-03-31
Vista Pharmaceuticals Inc00%2026-03-31
Dhananjaya Alli00%2026-03-31
Vasant V Alli00%2026-03-31
Vamsi V Alli00%2026-03-31
Roshni Alli00%2026-03-31
Padmavathi Alli00%2026-03-31
Pavan Sathvik Gilaka00%2026-03-31
Umakanth Katta00%2026-03-31
Murali Meraga00%2026-03-31
Suresh Gadalay00%2026-03-31
Kamal Gadalay00%2026-03-31
Board of Directors
NameDesignationYear
Dhananjaya AlliChairman / Executive Director / WTD2025
Murali MeragaExecutive Director & MD2025
Pavan Sathvik GilakaE D & Wholetime Director2025
Stanley Prabhakar ReddyNon Executive & Non WTD2025
Mallem Hanumantha RaoNon Executive & Non WTD2025
Umakanth KattaNon Executive & Non WTD2025
Divakar Reddy YerrabommanahalliNon Executive & Non WTD2025
Umesh Virupakah BanakarIndependent Non Exe. Director2025
Divya Bhavani ChakravarthulaIndependent Non Exe. Director2025
Naga Raja MadineniIndependent Non Exe. Director2025
Madhu Sudan AnchiIndependent Non Exe. Director2025
Swapna Priya GunduboinaIndependent Non Exe. Director2025
Anumala Ravi Chandra KumarIndependent Non Exe. Director2025
Rama Mohan ManamasaIndependent Non Exe. Director2025
Barkha JainCompany Sec. & Compli. Officer2025
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹2151212
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202500015015
202500015015
202500015015
Company Information
Incorporated1991
ChairmanDhananjaya Alli
AuditorA M Reddy & D R Reddy
Investor Email[email protected]
🌐 www.vistapharmaceuticals.com ↗

📍 Plot No 10to14 16to20 APIIC, Industrial Estate Chotyal, Nalgonda, Telangana

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Welcure Drugs & PharmaceuBharat Immunologicals & BSavita Oil TechnologiesKabsons Industries Ltd.Basant Agro Tech (India)Sandu Pharmaceuticals Ltd.Sun PharmaceuticalTitan Biotech Ltd.Bijoy Hans Ltd.Span Divergent LimitedJenburkt PharmaceuticalsHikalAll “52” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search